Is Embryo Genetic Testing in Georgia Accurate? Real Data & Process Analysis

Accuracy of Embryo Genetic Testing in Georgia: A Realistic Look from Process to Results

A patient who received a PGT-A report from a reproductive center in Tbilisi noticed the report stated "mosaicism rate 30%." She asked: Is this judgment really accurate? Could the embryo actually be normal? Behind this question lies a deep concern about the overall accuracy of embryo genetic testing. Not all laboratories can provide equally reliable answers, and not all embryos can be clearly diagnosed.

What is Embryo Genetic Testing?

The core technologies of embryo genetic testing include:

• PGT-A (Preimplantation Genetic Testing for Aneuploidy): Detects whether embryos have chromosomal number abnormalities, such as Trisomy 21, 45X, etc.
• PGT-M (Preimplantation Genetic Testing for Monogenic Disorders): Detects whether embryos carry pathogenic mutations for known monogenic genetic diseases (e.g., cystic fibrosis, thalassemia).
• PGT-SR (Preimplantation Genetic Testing for Structural Rearrangements): Used for structural abnormalities like chromosomal translocations and inversions.

Reproductive centers in Georgia commonly use Trophectoderm (TE) biopsy combined with Next-Generation Sequencing (NGS) technology. This is currently one of the international mainstream and most accurate approaches.

How Accurate Is It Exactly?

Most正规 reproductive centers in Georgia use NGS technology, achieving an accuracy rate for determining embryo chromosomal euploidy of over 95%. However, "accuracy" in a clinical context usually means: an embryo tested as euploid implants and develops into a healthy newborn after transfer. This final outcome is influenced by multiple factors including laboratory conditions, embryo quality, and maternal factors.

Why Do "Errors" Occur?

Main sources of error:

• Mosaicism Issues: The embryo itself has two or more cell lines (e.g., 20% abnormal + 80% normal). Biopsy only takes 5-10 cells, which might coincidentally sample abnormal cells or normal cells, leading to misdiagnosis of euploidy. The higher the mosaicism ratio, the greater the risk of misdiagnosis.
• Amplification Failure or Allele Dropout (ADO): During single-cell amplification, DNA amplification may be unbalanced, causing signal loss or erroneous amplification of a certain chromosomal region.
• Biopsy Technique Variation: Aspirating inner cell mass (affecting future embryo development) or debris (without nuclei) during biopsy leads to poor DNA quality.
• Laboratory Contamination: Very low probability.

How Do Laboratories in Georgia Respond?

First-tier laboratories will:

• Use double-layer DNA amplification + quality control samples, building a separate library for each embryo;
• Label the specific ratio for mosaic embryos (e.g., 30%);
• Recommend genetic counseling for priority implantation of embryos with high mosaicism (>50%);
• Use aCGH + FISH combined verification when necessary.

However, some smaller centers may only perform the lowest-cost qPCR, resulting in significantly lower accuracy.

Testing Value for Women of Different Ages

A 40-year-old woman underwent PGT-A at a center in Georgia. The test result showed only one euploid embryo, which was transferred and resulted in a successful delivery. This case illustrates that even at an age of declining egg quality, genetic testing can still screen out viable embryos.

How Does Georgia Compare with Other Countries?

• Top Centers in the US/Europe: Typically use NGS and have geneticists review each embryo, achieving similar accuracy (96%~98%), but costs 2-3 times higher.
• Mainstream Centers in Georgia: Also use NGS, with testing standards referencing ESHRE (European Society of Human Reproduction and Embryology) guidelines. However, limited by sample volume (possibly smaller numbers sent for testing), some centers have slightly less experience interpreting mosaicism.
• Thailand/Malaysia: Some laboratories still use aCGH or qPCR, with slightly lower accuracy.

When choosing a center in Georgia, you can ask to see its PGT-A validation data from the past year (e.g., clinical pregnancy rate, miscarriage rate after euploid embryo transfer).

The Most Easily Overlooked Detail: Biopsy Timing

The accuracy of embryo genetic testing is directly related to biopsy timing.

• Day 3 Cleavage Stage Biopsy: Takes only 1-2 cells, causes greater damage to the embryo, and has a high mosaicism misdiagnosis rate (about 10% false negative/false positive). This practice is largely phased out in Georgia.
• Day 5-6 Blastocyst Trophectoderm Biopsy: Takes 5-10 trophectoderm cells, causes less damage to the embryo, and has high accuracy. This is the current standard.
• Day 7 Blastocyst Biopsy: Although feasible, embryo quality is usually poorer, and result reliability is slightly reduced.

Confirm whether your chosen center exclusively uses Day 5/6 trophectoderm biopsy; this is the baseline for ensuring accuracy.

Common Pitfalls

1. Misbelieving in "Full Embryo Screening": PGT-A can only screen for chromosomal number abnormalities and structural anomalies >5Mb; it cannot detect monogenic diseases, microdeletions/duplications, triploidy, etc.
2. Ignoring Mosaicism Reports: Some centers may directly classify mosaic embryos as "abnormal" or "normal," posing risks of miscarriage or birth defects after transfer. Professional centers should provide the ratio and recommend genetic counseling.
3. Confusing "Accuracy Rate" with "Live Birth Rate": Even if an embryo is tested as euploid, implantation failure can still occur due to endometrial, immune, endocrine, or other factors. Accuracy refers only to the consistency between the test result and the embryo's true karyotype, not the live birth rate.
4. Over-reliance on Genetic Testing: For certain low-risk groups (young, no genetic history), PGT-A may lead to unnecessary embryo freezing damage or decision dilemmas regarding discarding embryos.

When Is It Suitable? When Is It Not?

Suitable Candidates:

• Female age ≥ 38 years;
• History of recurrent miscarriage (≥ 2 times);
• Repeated implantation failure (≥ 3 transfers of good quality embryos without implantation);
• Known carriers of balanced translocations, Robertsonian translocations, or other structural abnormalities;
• Known monogenic genetic diseases (requires combined PGT-M);
• Severe male factor (e.g., high sperm DNA fragmentation index).

Unsuitable Candidates:

• Young (< 35 years) with no adverse pregnancy history, solely pursuing "sex selection" or "improving success rate" (actual improvement in live birth rate is minimal);
• Very low ovarian reserve (AMH < 0.5 ng/mL), potentially unable to obtain enough embryos for biopsy;
• Presence of clear uterine structural abnormalities or immune issues, where the embryo itself is not the primary problem.

Specific Process and Timeline

1. Ovarian Stimulation and Egg Retrieval → Approximately 10-14 days
2. In Vitro Fertilization and Embryo Culture → 5-6 days to blastocyst stage
3. Trophectoderm Biopsy → Completed on the same day
4. Embryo Freezing (Vitrification) → Frozen immediately after biopsy
5. DNA Amplification and NGS Sequencing → 5-10 working days
6. Genetic Counseling and Report Interpretation → 1-2 days
7. Transfer of Euploid Embryo → Frozen-thawed embryo transfer (FET) after preparing the endometrium in a subsequent menstrual cycle

The entire cycle from stimulation to transfer takes about 1.5-2 months. If a fresh cycle transfer is used (immediately after results), it must be done within the ovulatory period, but Georgia mostly uses frozen cycles to improve implantation rates.

What Needs to Be Prepared?

• Karyotype Analysis of Both Partners (preferably G-banding, CMA if necessary);
• Detailed Family Pedigree of Genetic Diseases (especially for PGT-M);
• Chromosomal Analysis of Previous Miscarriage Tissue (if available);
• Confirm if the Center Holds International Accreditations (e.g., JCI, ISO15189, or collaboration with renowned European laboratories);
• Sign Informed Consent, clearly understanding the limitations and risks of the testing technology.

Risks and Precautions

• Biopsy Risk: Very few embryos stop developing after biopsy (<1%), but modern technology has significantly reduced this;
• Freezing Damage: Vitrification causes minimal damage to embryos, but a small number may have reduced survival rates after thawing;
• Psychological Risk: May discover all embryos are abnormal, leading to no embryos available for transfer; or may find mosaic embryos,陷入 "to transfer or not to transfer" decision dilemma.
• Financial Risk: PGT-A in Georgia costs approximately $1500-$3000 USD (excluding stimulation costs), and PGT-M is higher. If no euploid embryos are found after testing, this cost is non-refundable.

Practitioner Observations

An embryologist who has worked in Georgia for 5 years mentioned: The most overlooked issue is sample transport. If biopsied cells need to be sent to a foreign laboratory for testing (some centers in Georgia build their own libraries, others send to Germany/Cyprus/Russia), temperature fluctuations and delays during transport can affect DNA quality. Therefore, choosing a center with its own or a 24-hour partner laboratory is more reliable.

Special Reminder: Follow-up Advice for Mosaic Embryos

If the report shows "low-level mosaicism (<20%)" and there is clear evidence that the embryo continues to develop well after several hours of observation, some centers may recommend transfer with continuous prenatal monitoring. However, amniocentesis or chorionic villus sampling must be performed for final confirmation. If the mosaicism ratio is >50%, transfer is usually not recommended due to a higher risk of birth defects. This decision is individualized and requires in-depth analysis by a genetic counselor.

Suggestions for Next Steps

If you are considering embryo genetic testing in Georgia, you can:

1. Ask the center to provide a summary of PGT-A results from the last 12 months, including euploidy rate, pregnancy rate after transfer, and miscarriage rate;
2. Confirm if the laboratory participates in external quality control (e.g., providing quality assessment certificates like CAP, UK NEQAS);
3. Request a remote genetic counseling appointment to comprehensively assess risks and benefits before testing.

Accuracy is just a number; the key lies in the quality control, technical team, and individualized interpretation behind that number. In Georgia, choosing a laboratory and doctor with an international background can yield results and treatment experiences very close to European standards.